BCL2L11 (Bim), a terminal FoxO pathway node (hsa04068, P(non-)T-to-C = 1.26 × 10−6, one-sided Fisher’s exact test, Benjamini–Hochberg adjustment, n(non-)T-to-C = 30), established as anti-proliferative and apoptotic marker in breast cancer cells28, was revealed to be regulated by non-T-to-C peaks (Supplementary Fig. 6). This evidence concerns the gene BCL2L11 and breast carcinoma.